Monlunabant治疗糖尿病肾病的2期随机对照试验
这项2期、随机、双盲、安慰剂对照、多中心研究纳入254例糖尿病肾病成人患者,随机接受monlunabant 10 mg、25 mg或安慰剂每日一次口服16周。主要终点为UACR从基线至第16周的变化,结果显示25 mg组与安慰剂无统计学显著差异(ETR 0.72,95%CI 0.46-1.14),研究未能建立概念验证。
要点
- Monlunabant 25 mg组UACR较基线的几何最小二乘均值比为0.51,安慰剂组为0.71。
- 25 mg组与安慰剂比较ETR 0.72(95%CI 0.46-1.14),无统计学显著差异。
- UPCR和eGFR等次要终点与安慰剂比较未见差异。
核心结论
- 本研究未能建立monlunabant在糖尿病肾病中的概念验证,第16周UACR变化与安慰剂无显著差异。
- 较大的变异性及明显的安慰剂效应影响结果解读。
研究设计与样本
- 2期、随机、双盲、安慰剂对照、多中心研究,纳入糖尿病肾病成人患者。
- 参与者按1:1:1随机接受monlunabant 10 mg、25 mg或安慰剂口服片每日一次,治疗16周。
- 全分析集共254例(10 mg组85例、25 mg组86例、安慰剂组83例)。
主要发现
- 第16周UACR较基线的几何最小二乘均值比:10 mg组0.58、25 mg组0.51、安慰剂组0.71。
- 25 mg组与安慰剂比较ETR 0.72(95%CI 0.46-1.14),无统计学显著差异,故未对10 mg组进行正式检验(ETR 0.82,95%CI 0.53-1.27)。
- 次要终点UPCR和eGFR与安慰剂比较未见差异。
- 最常见不良事件为轻至中度胃肠道疾病,以恶心、呕吐和腹泻为主,因不良事件退出率随monlunabant剂量增加而升高。
关键数值与推荐
- 主要终点为UACR从基线至第16周的变化。
- 次要终点包括UPCR和eGFR的变化。
临床怎么用
- Monlunabant 10 mg和25 mg在糖尿病肾病患者中未显著降低UACR,不推荐用于该适应症。
- 需关注胃肠道不良反应及剂量相关的退出率增加。
局限性
- 较大的变异性及明显的安慰剂效应影响结果解读。
- 因25 mg组与安慰剂无显著差异,未对10 mg组进行正式统计检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diabetic kidney disease (DKD) is a significant complication of diabetes, and an unmet need remains for new therapeutic options. Here, we investigated the efficacy and safety of monlunabant, a second-generation cannabinoid receptor 1 inverse agonist, in individuals with DKD. METHODS: This phase 2, randomized, double-blind, placebo-controlled, multicenter study, enrolled adults with DKD. Participants were randomized (1:1:1) to receive oral tablets of monlunabant 10 mg or 25 mg, or placebo once daily for 16 weeks. The primary endpoint was the change in urine albumin-to-creatinine ratio (UACR) from baseline to week 16. Secondary endpoints included changes in urine protein-to-creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR). RESULTS: In total, 254 participants formed the full analysis set (85, 86, and 83 in the 10 mg, 25 mg, and placebo groups, respectively). At week 16, the estimated geometric least squares mean ratios to baseline for UACR were 0.58, 0.51, and 0.71 in the 10 mg, 25 mg, and placebo groups, respectively. Monlunabant 25 mg did not show statistically significant differences compared to placebo (estimated treatment ratio [ETR] 0.72, 95% confidence interval (0.46 to 1.14)). Therefore, formal testing was not performed for 10 mg compared to placebo (ETR 0.82 (0.53 to 1.27)). Secondary endpoints showed similar trends, with no differences in UPCR or eGFR, when compared to placebo. The most frequently reported adverse events were mild to moderate gastrointestinal disorders, driven by nausea, vomiting, and diarrhea. Participant withdrawals increased with monlunabant dose. CONCLUSIONS: Our study failed to establish proof of concept of monlunabant in DKD, as the effect on UACR at week 16 was not significantly different from placebo. However, greater than anticipated variability and a large placebo response affect interpretation. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT05514548.
引用
- Cherney DZI, Bonefeld K, Crater G, et al. A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease. Kidney Int. 2026. PMID: 41866124. doi:10.1016/j.kint.2026.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。